[go: up one dir, main page]

NZ754706A - Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus - Google Patents

Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus

Info

Publication number
NZ754706A
NZ754706A NZ754706A NZ75470617A NZ754706A NZ 754706 A NZ754706 A NZ 754706A NZ 754706 A NZ754706 A NZ 754706A NZ 75470617 A NZ75470617 A NZ 75470617A NZ 754706 A NZ754706 A NZ 754706A
Authority
NZ
New Zealand
Prior art keywords
treat
gestational diabetes
diabetes mellitus
lactic acid
acid bacteria
Prior art date
Application number
NZ754706A
Inventor
Kristin Lee Wickens
Original Assignee
Univ Of Otago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Otago filed Critical Univ Of Otago
Publication of NZ754706A publication Critical patent/NZ754706A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Dairy Products (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides methods of treating or preventing gestational diabetes by administering Lactobacillus rhamnosusHN001 or derivatives thereof, in addition to uses, compositions, and medicaments comprising Lactobacillus rhamnosusHN001 or derivatives thereof to treat or prevent gestational diabetes mellitus.
NZ754706A 2016-12-22 2017-06-02 Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus NZ754706A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ72791416 2016-12-22
PCT/IB2017/053262 WO2018115985A1 (en) 2016-12-22 2017-06-02 Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus

Publications (1)

Publication Number Publication Date
NZ754706A true NZ754706A (en) 2022-09-30

Family

ID=62624701

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ754706A NZ754706A (en) 2016-12-22 2017-06-02 Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus

Country Status (14)

Country Link
US (2) US11395839B2 (en)
EP (1) EP3558330B1 (en)
JP (1) JP7092380B2 (en)
KR (1) KR102513639B1 (en)
CN (1) CN110290795A (en)
AU (1) AU2017380603B2 (en)
CA (1) CA3047920C (en)
DK (1) DK3558330T3 (en)
MX (1) MX2019007555A (en)
MY (1) MY197917A (en)
NZ (1) NZ754706A (en)
PH (1) PH12019501439B1 (en)
RU (1) RU2769312C2 (en)
WO (1) WO2018115985A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110290795A (en) * 2016-12-22 2019-09-27 奥塔哥大学 Use of lactic acid bacteria in the treatment or prevention of gestational diabetes mellitus
EP4014756A1 (en) * 2020-12-15 2022-06-22 DuPont Nutrition Biosciences ApS Bioprocessing of protein with probiotic bacteria to improve amino acid and peptide availability
CN117015309A (en) * 2020-12-22 2023-11-07 方塔拉合作集团有限公司 Use of Lactobacilli to inhibit the growth of methanogens or reduce methane emissions
CN114990004B (en) * 2022-04-19 2023-09-15 尚品健康科技(青岛)有限公司 Secretory immunoglobulin A-packaged lactobacillus reuteri and application thereof in preventing and treating gestational diabetes
WO2024158981A1 (en) * 2023-01-26 2024-08-02 Wisconsin Alumni Research Foundation Compositions and methods for reducing the rate of type 1 diabetes
CN116694537B (en) * 2023-07-28 2023-10-31 善恩康生物科技（苏州）有限公司 Lactobacillus rhamnosus and its application in the preparation of products for the treatment of type 2 diabetes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110972A (en) 1996-07-01 2000-08-29 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (S)-tridihexethyl
RU2208632C2 (en) 1997-08-21 2003-07-20 Нью Зиланд Дэйри Борд Immunostimulating strain lactobacillus rhamnosus (variants), composition for immunity enhancement (variants), method of immunity enhancement (variants)
US20030191193A1 (en) 2002-04-03 2003-10-09 Jillian Cornish Lactoferrin
AU2006300009A1 (en) 2005-10-14 2007-04-19 Auckland Uniservices Limited Use of lactoferrin fragments and hydrolysates
AR060029A1 (en) 2006-03-02 2008-05-21 Unistraw Patent Holdings Ltd DRINK STRAW ADAPTED FOR PROGRESSIVELY CONDITIONING AN ACTIVE INGREDIENT AND METHOD OF MANUFACTURING SUCH PAJILLA
TW200841847A (en) 2006-11-06 2008-11-01 Unistraw Patent Holdings Ltd Functional filter for drinking straw
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
MX2011005527A (en) * 2008-11-28 2011-09-28 Univ Otago Use of lactic acid bacteria to treat or prevent eczema.
EP2525811B2 (en) * 2010-01-19 2019-02-27 Abbott Laboratories A composition comprising lactobacillus rhamnosus hn001 and prebiotics for use in the treatment of allergic lung disease
BR112017023636B1 (en) 2015-06-11 2021-11-03 Société des Produits Nestlé S.A. ORAL COMPOSITION
CN110290795A (en) * 2016-12-22 2019-09-27 奥塔哥大学 Use of lactic acid bacteria in the treatment or prevention of gestational diabetes mellitus

Also Published As

Publication number Publication date
BR112019012965A2 (en) 2019-11-26
WO2018115985A1 (en) 2018-06-28
EP3558330B1 (en) 2022-09-21
US12377125B2 (en) 2025-08-05
PH12019501439B1 (en) 2024-02-23
RU2019122811A (en) 2021-01-25
EP3558330A1 (en) 2019-10-30
CN110290795A (en) 2019-09-27
US20200093873A1 (en) 2020-03-26
RU2769312C2 (en) 2022-03-30
JP2020502247A (en) 2020-01-23
KR20190107032A (en) 2019-09-18
MX2019007555A (en) 2020-01-30
EP3558330A4 (en) 2020-07-08
JP7092380B2 (en) 2022-06-28
KR102513639B1 (en) 2023-03-23
AU2017380603B2 (en) 2022-02-03
PH12019501439A1 (en) 2020-02-24
DK3558330T3 (en) 2022-11-07
CA3047920A1 (en) 2018-06-28
US20220387527A1 (en) 2022-12-08
AU2017380603A1 (en) 2019-07-11
MY197917A (en) 2023-07-25
US11395839B2 (en) 2022-07-26
CA3047920C (en) 2022-07-19
RU2019122811A3 (en) 2021-01-25

Similar Documents

Publication Publication Date Title
PH12019502725A1 (en) Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2019009132A (en) Synergistic bacterial compositions and methods of production and use thereof.
NZ754706A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
MX2015002177A (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections.
MX340533B (en) 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections.
MX2016006221A (en) Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children.
MX2016012574A (en) Substituted heteroaryl compounds and methods of use.
MX2017012545A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections.
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
MX2016009251A (en) 7-oxo-1,6-diazabicyclo[3.2.1 ]octane derivatives and their use as antibacterial agents.
EA033446B1 (en) Heterocyclic compound for treating macular degeneration and/or stargardt's disease
MX379201B (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2023005014A (en) Methods of treating chronic inflammatory diseases.
MX378607B (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2017012535A (en) Novel heterocyclic compounds and their use in preventing or treating bacterial infections.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12020552241A1 (en) Use of polar lipids to treat or prevent gestational diabetes mellitus
MX2017014080A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections.
MX2015005733A (en) Tricyclic compounds for use in the treatment and/or control of obesity.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2017012539A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections.
GB201115977D0 (en) Neurodevelopmental disorders

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2024 BY ANAQUA SERVICES

Effective date: 20230523

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2025 BY ANAQUA SERVICES

Effective date: 20240521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2026 BY ANAQUA SERVICES

Effective date: 20250520